Pasithea Therapeutics Corp., a publicly traded biotechnology company in Florida focused on research and development for central nervous system disorders, has acquired Woodbridge-based AlloMek Therapeutics LLC.
The purchase expands Pasithea Therapeutics’ pipeline of central nervous system-focused drug development, the Miami Beach-based company said.
AlloMek Therapeutics is a privately held biotechnology company with offices in Woodbridge and Palo Alto, California focused on developing medications for treating rare diseases.